Recent Updates
Recently added Catalysts

INS37217

Phase 2

Perennial Allergic Rhinitis | Small molecule | Other |Merck & Company, Inc.|Last Updated: Jan 25, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment630
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00210015A Study in Subjects With Perennial Allergic RhinitisPHASE2 COMPLETED 630Dec 1, 2002Apr 1, 2003Jan 25, 2016 -
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
total nasal symptom score
Secondary Endpoints
average total nasal symptom scores over various timepoints average individual symptom scores
global assessment of perennial allergic rhinitis symptoms
instantaneous assessment of symptoms
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
INS37217 Nasal SprayDRUG -
Unlock Study Design Details
Eligibility Criteria
Healthy VolunteersNo

Inclusion Criteria: * Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing. * Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies. * Have not sta...

Unlock Eligibility Criteria